Literature DB >> 3905609

Protection by Candida albicans of Staphylococcus aureus in the establishment of dual infection in mice.

E Carlson, G Johnson.   

Abstract

Candida albicans has been shown to stimulate infection in mice by a number of bacteria when both organisms are inoculated intraperitoneally (E. Carlson, Infect. Immun. 39:193-197, 1983). When subcutaneous and intraperitoneal inoculations were given with Staphylococcus aureus and C. albicans injected at opposite sites, mixed infection was established at the site of fungal inoculation but not at the site of the bacterial injection. Histopathologic evaluation of tissues for the presence of C. albicans and S. aureus after intraperitoneal inoculation of both showed fungal growth in the mesentery and omentum of the abdominal cavity. Cocci were numerous and always associated with the fungi, located within the fungal growth rather than at its periphery. It was concluded that this growth pattern in some way protected the bacteria and was the basis for the generalized fungal stimulation of the bacterial infections observed. In addition to C. albicans, Candida stellatoidea, Candida tropicalis, Candida parapsilosis, Torulopsis glabrata, and heat-inactivated C. albicans also demonstrated some ability to protect bacteria injected simultaneously, although C. parapsilosis and T. glabrata were less effective than the other yeasts in this respect.

Entities:  

Mesh:

Year:  1985        PMID: 3905609      PMCID: PMC261128          DOI: 10.1128/iai.50.3.655-659.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

Review 1.  SPECIFIC AND NONSPECIFIC IMMUNITY IN CANDIDA INFECTIONS. EXPERIMENTAL STUDIES OF THE ROLE OF CANDIDA CELL CONSTITUENTS AND REVIEW OF LITERATURE.

Authors:  B DOBIAS
Journal:  Acta Med Scand       Date:  1964

2.  Thymoma and pancytopenia; report of a case and review of the literature.

Authors:  J W JOSSE; S I ZACKS
Journal:  N Engl J Med       Date:  1958-07-17       Impact factor: 91.245

3.  Acquired hypogammaglobulinemia in an adult; report of a case, with clinical and experimental studies.

Authors:  C M MARTIN; R S GORDON; N B MCCULLOUGH
Journal:  N Engl J Med       Date:  1956-03-08       Impact factor: 91.245

4.  Estimation of LD50 by moving averages.

Authors:  B M BENNETT
Journal:  J Hyg (Lond)       Date:  1952-06

5.  Staphylococcus aureus and Candida albicans infection (animal experiments).

Authors:  F Staib; G Grosse; S K Mishra
Journal:  Zentralbl Bakteriol Orig A       Date:  1976-05

6.  Mucocutaneous candidiasis or mucocutaneous microbiosis?

Authors:  R R Chappler; H I Maibach; M A Conant
Journal:  JAMA       Date:  1978-01-30       Impact factor: 56.272

7.  IgE antibodies to Staphylococcus aureus and Candida albicans in patients with the syndrome of hyperimmunoglobulin E and recurrent infections.

Authors:  M Berger; C H Kirkpatrick; P K Goldsmith; J I Gallin
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

8.  Esophageal, gastric, and intestinal candidiasis.

Authors:  J S Trier; D J Bjorkman
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

9.  Effect of strain of Staphylococcus aureus on synergism with Candida albicans resulting in mouse mortality and morbidity.

Authors:  E Carlson
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

10.  Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice.

Authors:  E Carlson
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

View more
  29 in total

Review 1.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance.

Authors:  Melphine M Harriott; Mairi C Noverr
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 3.  Medically important bacterial-fungal interactions.

Authors:  Anton Y Peleg; Deborah A Hogan; Eleftherios Mylonakis
Journal:  Nat Rev Microbiol       Date:  2010-03-29       Impact factor: 60.633

Review 4.  Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota.

Authors:  Sarah Höfs; Selene Mogavero; Bernhard Hube
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

5.  Systemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue.

Authors:  Lisa Marie Schlecht; Brian M Peters; Bastiaan P Krom; Jeffrey A Freiberg; Gertrud M Hänsch; Scott G Filler; Mary Ann Jabra-Rizk; Mark E Shirtliff
Journal:  Microbiology       Date:  2014-10-20       Impact factor: 2.777

6.  Functional regions of Candida albicans hyphal cell wall protein Als3 that determine interaction with the oral bacterium Streptococcus gordonii.

Authors:  Caroline V Bamford; Angela H Nobbs; Michele E Barbour; Richard J Lamont; Howard F Jenkinson
Journal:  Microbiology       Date:  2014-10-20       Impact factor: 2.777

7.  Tumor necrosis factor (TNF) is induced in mice by Candida albicans: role of TNF in fibrinogen increase.

Authors:  L Riipi; E Carlson
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

Review 8.  Importance of Candida-bacterial polymicrobial biofilms in disease.

Authors:  Melphine M Harriott; Mairi C Noverr
Journal:  Trends Microbiol       Date:  2011-08-19       Impact factor: 17.079

9.  Microbial interactions and differential protein expression in Staphylococcus aureus -Candida albicans dual-species biofilms.

Authors:  Brian M Peters; Mary Ann Jabra-Rizk; Mark A Scheper; Jeff G Leid; John William Costerton; Mark E Shirtliff
Journal:  FEMS Immunol Med Microbiol       Date:  2010-06-07

10.  Prevalence and spectrum of bacterial co-infection during fungal keratitis.

Authors:  J C Pate; D B Jones; K R Wilhelmus
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.